Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)
34.42
+0.09 (0.26%)
Crinetics Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases and disorders
The company leverages its expertise in the field of endocrine science to discover and create targeted treatments that address unmet medical needs. Crinetics aims to provide effective solutions for patients suffering from conditions related to hormonal imbalances by advancing its pipeline of novel compounds through various stages of clinical development. Through its commitment to research and development, the company strives to enhance the quality of life for individuals affected by complex endocrine issues.
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit Therapeutics, Plug Power and XPeng Inc.
Neurocrine's Crenessity receives FDA approval as a groundbreaking adjunctive treatment for classic CAH, offering a novel approach to hormone regulation.
CRNX stock results show that Crinetics Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
CRNX stock results show that Crinetics Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Crinetics Pharmaceuticals unveils PATHFNDR-2 Phase 3 results for paltusotine in acromegaly treatment. Statistically significant efficacy & safety, with plans for FDA submission in 2024.
